Reynders McVeigh Capital Management LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 4.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 25,188 shares of the medical device company’s stock after selling 1,200 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in DexCom were worth $2,029,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Crewe Advisors LLC bought a new position in DexCom during the second quarter valued at approximately $26,000. Sound Income Strategies LLC increased its stake in shares of DexCom by 300.0% during the 3rd quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock worth $26,000 after purchasing an additional 240 shares during the last quarter. Bivin & Associates Inc. raised its holdings in shares of DexCom by 300.0% during the 2nd quarter. Bivin & Associates Inc. now owns 360 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 270 shares in the last quarter. Ronald Blue Trust Inc. lifted its stake in shares of DexCom by 860.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 327 shares during the last quarter. Finally, Private Trust Co. NA bought a new stake in DexCom in the second quarter worth $29,000. 94.01% of the stock is owned by institutional investors and hedge funds.
DexCom Price Performance
Shares of NASDAQ:DXCM traded up $1.25 during midday trading on Thursday, reaching $108.96. 298,541 shares of the company’s stock were exchanged, compared to its average volume of 2,441,416. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.43 and a current ratio of 3.77. The company’s 50 day simple moving average is $112.05 and its two-hundred day simple moving average is $100.41. DexCom, Inc. has a 12 month low of $66.89 and a 12 month high of $134.76. The firm has a market capitalization of $42.09 billion, a PE ratio of 198.55, a price-to-earnings-growth ratio of 2.93 and a beta of 1.11.
Wall Street Analyst Weigh In
Insiders Place Their Bets
In other news, CFO Jereme M. Sylvain sold 2,400 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $112.62, for a total value of $270,288.00. Following the sale, the chief financial officer now directly owns 67,237 shares in the company, valued at approximately $7,572,230.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 2,400 shares of the company’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $112.62, for a total value of $270,288.00. Following the sale, the chief financial officer now directly owns 67,237 shares in the company, valued at $7,572,230.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul R. Flynn sold 8,988 shares of DexCom stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $123.50, for a total value of $1,110,018.00. Following the transaction, the executive vice president now directly owns 55,744 shares of the company’s stock, valued at $6,884,384. The disclosure for this sale can be found here. Insiders sold a total of 116,876 shares of company stock worth $12,562,898 over the last quarter. Company insiders own 0.41% of the company’s stock.
DexCom Company Profile
DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air’s Recent Earnings
- Apple’s Earnings, Expectations and Surprises
- T-Mobile Delivers Where it Matters Most to Investors
- Exxon Mobil Could Gush To New Highs Very Soon
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Get Rating).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.